Base de dados : MEDLINE
Pesquisa : D02.886.369.575 [Categoria DeCS]
Referências encontradas : 150 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 15 ir para página                         

  1 / 150 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24930580
[Au] Autor:Tybura P; Trzesniowska-Drukala B; Bienkowski P; Beszlej A; Frydecka D; Mierzejewski P; Samochowiec A; Grzywacz A; Samochowiec J
[Ad] Endereço:Department of Psychiatry, Pomeranian Medical University, ul. Broniewskiego 26, 71-460 Szczecin, Poland.
[Ti] Título:Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.
[So] Source:Psychiatry Res;219(2):261-7, 2014 Oct 30.
[Is] ISSN:1872-7123
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:The primary aim of the present study was to assess the possible associations between dopaminergic, serotonergic, and glutamatergic system-related genes and adverse events after antipsychotic treatment in paranoid schizophrenia patients. The second aim of the study was to compare the intensity of these symptoms between atypical (ziprasidone and olanzapine) and typical (perazine) antipsychotic drugs. One-hundred and ninety-one Polish patients suffering from paranoid schizophrenia were genotyped for polymorphisms of DRD2, DAT1, COMT, MAOA, SERT, 5HT2A, and GRIK3. The patients were randomized to treatment with perazine, olanzapine or ziprasidone monotherapy for 3 months. The intensity of side effects (changes in body weights and extrapyramidal symptoms (EPS)) was measured at baseline and after 12 weeks of antipsychotic treatment. After 3 months of therapy, the weight increase was the greatest in the group treated with olanzapine and the least in the group treated with ziprasidone. None of the examined gene polymorphisms was associated with the body weight changes. Perazine treatment was associated with the significantly highest intensity of EPS. None of the examined polymorphisms was associated with the changes in extrapyramidal adverse events after antipsychotic treatment. The selected polymorphisms are not primarily involved in changes in body weights and EPS related to antipsychotic treatment in paranoid schizophrenia patients.
[Mh] Termos MeSH primário: Antipsicóticos/efeitos adversos
Doenças dos Gânglios da Base/induzido quimicamente
Benzodiazepinas/efeitos adversos
Sobrepeso/induzido quimicamente
Perazina/efeitos adversos
Piperazinas/efeitos adversos
Esquizofrenia Paranoide/tratamento farmacológico
Tiazóis/efeitos adversos
Ganho de Peso/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adulto
Antipsicóticos/uso terapêutico
Doenças dos Gânglios da Base/genética
Benzodiazepinas/uso terapêutico
Catecol O-Metiltransferase/genética
Proteínas da Membrana Plasmática de Transporte de Dopamina/genética
Feminino
Genótipo
Seres Humanos
Masculino
Meia-Idade
Monoaminoxidase/genética
Sobrepeso/genética
Perazina/uso terapêutico
Piperazinas/uso terapêutico
Polimorfismo Genético
Receptor 5-HT2A de Serotonina/genética
Receptores de Dopamina D2/genética
Receptores de Ácido Caínico/genética
Esquizofrenia Paranoide/genética
Proteínas da Membrana Plasmática de Transporte de Serotonina/genética
Tiazóis/uso terapêutico
Ganho de Peso/genética
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (DRD2 protein, human); 0 (Dopamine Plasma Membrane Transport Proteins); 0 (GluK3 kainate receptor); 0 (Piperazines); 0 (Receptor, Serotonin, 5-HT2A); 0 (Receptors, Dopamine D2); 0 (Receptors, Kainic Acid); 0 (SLC6A3 protein, human); 0 (SLC6A4 protein, human); 0 (Serotonin Plasma Membrane Transport Proteins); 0 (Thiazoles); 12794-10-4 (Benzodiazepines); 6UKA5VEJ6X (ziprasidone); 8915147A2B (Perazine); EC 1.4.3.4 (Monoamine Oxidase); EC 2.1.1.6 (COMT protein, human); EC 2.1.1.6 (Catechol O-Methyltransferase); N7U69T4SZR (olanzapine)
[Em] Mês de entrada:1412
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140617
[St] Status:MEDLINE


  2 / 150 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:24425538
[Au] Autor:Leucht S; Helfer B; Hartung B
[Ad] Endereço:Klinik und Poliklinik für Psychiatrie und Psychotherapie, Technische Universität München Klinikum rechts der Isar, Ismaningerstrasse 22, München, Germany, 81675.
[Ti] Título:Perazine for schizophrenia.
[So] Source:Cochrane Database Syst Rev;(1):CD002832, 2014 Jan 15.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Perazine is an old phenothiazine derivative used for the treatment of people with schizophrenia and is reputed to have a low level of extrapyramidal adverse effects. As far as we are aware, its use is limited to Germany, Poland, the former Yugoslavia and the Netherlands. OBJECTIVES: To examine the effects of perazine for those with schizophrenia or related psychoses in comparison with placebo, no treatment or other antipsychotic medications. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register, which includes relevant randomised controlled trials from the bibliographic databases Biological Abstracts, CINAHL, The Cochrane Library, EMBASE, MEDLINE, PsycLIT, LILACS, PSYNDEX, Sociological Abstracts and Sociofile. We searched the references of all included studies for further trials. We contacted pharmaceutical companies and authors of trials. We updated this search on 16th July 2012. SELECTION CRITERIA: We selected all randomised controlled trials that compared perazine with other treatments for people with schizophrenia or schizophrenia-like psychoses, or both. DATA COLLECTION AND ANALYSIS: The review authors (SL, BH, BHe) independently inspected the citations and where possible abstracts and ordered papers for re-inspection and quality assessment. We independently extracted data. We calculated the risk ratio (RR) and 95% confidence interval (CI) using a random-effects model. For continuous data, we calculated mean differences (MD). We inspected all data for heterogeneity, assessed trials for risk of bias and created summary of findings tables using GRADE. MAIN RESULTS: The review now includes seven trials with a total of 479 participants. In only one trial, with 95 participants, perazine appeared superior to 'active placebo' (trimipramine) at five weeks for the outcome of 'no important global improvement' (n = 95, RR 0.43 CI 0.2 to 0.8, low quality evidence), but there was no statistically significant difference in most measures of mental state. Perazine did not induce more general adverse events than placebo but more participants received at least one dose of antiparkinson medication (n = 95, RR 4.50 CI 1.0 to 19.5, very low quality evidence).Six small trials comparing perazine with other antipsychotics, including 384 participants in total, were incompletely reported and the outcomes were presented in various ways so that meta-analysis was not possible on most occasions. In the six studies, a similar number of participants receiving perazine or comparator antipsychotics (amisulpride, haloperidol, olanzapine, ziprasidone, zotepine) left the studies early (n = 384, RR 0.97 CI 0.68 to 1.38, low quality evidence). The results on efficacy could not be meta-analysed because the authors presented their results in very different ways. No obvious differences in adverse events between perazine and other antipsychotics could be derived from the limited data. Two haloperidol comparisons did not present extrapyramidal side-effects in a way that was suitable for use in meta-analysis, but three small comparisons with the second-generation antipsychotics zotepine and amisulpride showed no higher risk of akathisia (n = 111, RR 0.31 CI 0.1 to 1.1), dyskinesia (n = 111, RR 0.47 CI 0.1 to 3.5), parkinsonism (n = 81, RR 1.21 CI 0.5 2.8) or tremor (n = 40, RR 0.80 CI 0.3 to 2.6) with perazine. AUTHORS' CONCLUSIONS: The number, size and reporting of randomised controlled perazine trials are insufficient to present firm conclusions about the properties of this antipsychotic. It is possible that perazine is associated with a similar risk of extrapyramidal side-effects as some atypical antipsychotics but this is based on small comparisons. This should be clarified in larger, well-designed trials.
[Mh] Termos MeSH primário: Antipsicóticos/uso terapêutico
Perazina/uso terapêutico
Esquizofrenia/tratamento farmacológico
[Mh] Termos MeSH secundário: Antipsicóticos/efeitos adversos
Seres Humanos
Perazina/efeitos adversos
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Antipsychotic Agents); 8915147A2B (Perazine)
[Em] Mês de entrada:1407
[Cu] Atualização por classe:160602
[Lr] Data última revisão:
160602
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140116
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD002832.pub3


  3 / 150 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:24946464
[Au] Autor:Tybura P; Mak M; Samochowiec A; Pelka-Wysiecka J; Grzywacz A; Grochans E; Zaremba-Pechmann L; Samochowiec J
[Ti] Título:[The influence of antipsychotic therapy on the cognitive functions of schizophrenic patients].
[Ti] Título:Wplyw leków przeciwpsychotycznych na funkcje poznawcze u pacjentów ze schizofrenia..
[So] Source:Psychiatr Pol;47(4):567-78, 2013 Jul-Aug.
[Is] ISSN:0033-2674
[Cp] País de publicação:Poland
[La] Idioma:pol
[Ab] Resumo:AIM: The aim of the present study was twofold: 1. to compare the efficacy of three antipsychotics (ziprasidone, olanzapine and perazine) in schizophrenia 2. to compare the improvement in cognitive functioning between groups treated with the three different neuroleptics. METHOD: A total of 58 Caucasian patients diagnosed with paranoid schizophrenia were recruited into the study group. We used the Polish version of the CIDI (Composite International Diagnostic Interview) to obtain ICD-10 diagnoses. The intensity of psychopathological symptoms was examined using the PANSS. The patients were randomly assigned to treatment with perazine, olanzapine or ziprasidone administered as monotherapy for 3 months. The treatment efficacy was measured as a change in the PANSS (Positive and Negative Syndrome Scale) total score from baseline (T0) to 3 months (T1). The WCST (The Wisconsin Card Sorting Test) was used to measure working memory and executive functions in the evaluated patients. Wilcoxon's and Kruskal-Wallis tests were applied to compare changes in the PANSS scores between the treatment groups. To analyze the cognitive functions, Kruskal-Wallis test for the WCST parameters was used. RESULTS: The three antipsychotics similarly reduced the total PANSS score. The WCST parameters in the 3 groups of examined patients using the Kruskal-Wallis test revealed some differences between the three administered antipsychotics. CONCLUSIONS: Results suggest that the short-term efficacy of the atypical (olanzapine, ziprasidone) and typical (perazine) antipsychotic drugs did not differ. Based on the analysis, a conclusion can be drawn that the three neuroleptics provided similar improvements in cognitive functioning.
[Mh] Termos MeSH primário: Antipsicóticos/uso terapêutico
Benzodiazepinas/uso terapêutico
Transtornos Cognitivos/prevenção & controle
Cognição/efeitos dos fármacos
Perazina/uso terapêutico
Piperazinas/uso terapêutico
Esquizofrenia/tratamento farmacológico
Tiazóis/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Transtornos Cognitivos/etiologia
Relação Dose-Resposta a Droga
Feminino
Seres Humanos
Masculino
Meia-Idade
Esquizofrenia/complicações
Psicologia do Esquizofrênico
Índice de Gravidade de Doença
Método Simples-Cego
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Piperazines); 0 (Thiazoles); 12794-10-4 (Benzodiazepines); 6UKA5VEJ6X (ziprasidone); 8915147A2B (Perazine); N7U69T4SZR (olanzapine)
[Em] Mês de entrada:1409
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140621
[St] Status:MEDLINE


  4 / 150 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23954492
[Au] Autor:Hempel C; Nörenberg W; Sobottka H; Urban N; Nicke A; Fischer W; Schaefer M
[Ad] Endereço:Rudolf-Boehm-Institute of Pharmacology and Toxicology, Medical Faculty, University of Leipzig, Härtelstrasse 16-18, 04107 Leipzig, Germany.
[Ti] Título:The phenothiazine-class antipsychotic drugs prochlorperazine and trifluoperazine are potent allosteric modulators of the human P2X7 receptor.
[So] Source:Neuropharmacology;75:365-79, 2013 Dec.
[Is] ISSN:1873-7064
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:P2X7, an ATP-gated cation channel, is involved in immune cell activation, hyperalgesia and neuropathic pain. By regulating cytokine release in the brain, P2X7 has been linked to the pathophysiology of mood disorders and schizophrenia. We here assess the impact of 123 drugs that act in the central nervous system on human P2X7. Most prominently, the tricyclic antipsychotics prochlorperazine (PCP) and trifluoperazine (TFP) potently inhibited P2X7-mediated Ca2+ entry, dye permeation and ionic currents. In divalent cation-containing bath solutions or after prolonged incubation, ATP-evoked P2X7 currents were inhibited by 10 µM PCP. This effect was not related to dopamine receptor antagonism. Surprisingly, PCP co-applied with ATP enhanced inward currents in bath solutions with low divalent cation concentrations. Intracellular perfusion with PCP did not substitute for the extracellularly applied drug, indicating that its binding sites are accessible from the extracellular space. Since P2X7 current potentiation by PCP was voltage-dependent, at least one site may be located within the electrical field of the membrane. While the channel opening and closure kinetic was altered by PCP, the apparent affinity of ATP remained unchanged (potentiation) or changed slightly (inhibition). Measurements in human monocyte-derived macrophages confirmed the PCP-induced inhibition of ATP-evoked Ca2+ influx, Yo-Pro-1 permeability, and whole cell currents. Interestingly, neither heterologously expressed rat or mouse P2X7 nor native P2X7 in rat astrocyte cultures or in mouse bone marrow-derived macrophages were inhibited by perazines with a similar potency. We conclude that perazine-type neuroleptics are potent, but species-selective allosteric modulators of human but not murine P2X7 receptors.
[Mh] Termos MeSH primário: Antipsicóticos/farmacologia
Proclorperazina/farmacologia
Receptores Purinérgicos P2X7/metabolismo
Trifluoperazina/farmacologia
[Mh] Termos MeSH secundário: Trifosfato de Adenosina/farmacologia
Regulação Alostérica/efeitos dos fármacos
Animais
Benzodiazepinonas/farmacologia
Benzoxazóis/metabolismo
Cálcio/metabolismo
Relação Dose-Resposta a Droga
Células HEK293
Seres Humanos
Potenciais da Membrana/efeitos dos fármacos
Técnicas de Patch-Clamp
Perazina/farmacologia
Antagonistas do Receptor Purinérgico P2X/farmacologia
Compostos de Quinolínio/metabolismo
Receptores Purinérgicos P2X7/genética
Fatores de Tempo
Transfecção
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro(3,2-e)-1,4-diazepin-2-one); 0 (Antipsychotic Agents); 0 (Benzodiazepinones); 0 (Benzoxazoles); 0 (Purinergic P2X Receptor Antagonists); 0 (Quinolinium Compounds); 0 (Receptors, Purinergic P2X7); 152068-09-2 (YO-PRO 1); 214IZI85K3 (Trifluoperazine); 8915147A2B (Perazine); 8L70Q75FXE (Adenosine Triphosphate); SY7Q814VUP (Calcium); YHP6YLT61T (Prochlorperazine)
[Em] Mês de entrada:1408
[Cu] Atualização por classe:131216
[Lr] Data última revisão:
131216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130820
[St] Status:MEDLINE


  5 / 150 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23397051
[Au] Autor:Fischer M; Unterecker S; Deckert J; Pfuhlmann B
[Ti] Título:Elevated clozapine serum levels in combination with perazine.
[So] Source:Psychopharmacology (Berl);226(3):623-5, 2013 Apr.
[Is] ISSN:1432-2072
[Cp] País de publicação:Germany
[La] Idioma:eng
[Mh] Termos MeSH primário: Antipsicóticos/farmacocinética
Clozapina/farmacocinética
Perazina/farmacologia
[Mh] Termos MeSH secundário: Adulto
Antipsicóticos/farmacologia
Antipsicóticos/uso terapêutico
Clozapina/análogos & derivados
Clozapina/sangue
Clozapina/uso terapêutico
Relação Dose-Resposta a Droga
Interações Medicamentosas
Feminino
Seres Humanos
Masculino
Meia-Idade
Perazina/uso terapêutico
Esquizofrenia Catatônica/tratamento farmacológico
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Antipsychotic Agents); 1I9001LWY8 (norclozapine); 8915147A2B (Perazine); J60AR2IKIC (Clozapine)
[Em] Mês de entrada:1308
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130212
[St] Status:MEDLINE
[do] DOI:10.1007/s00213-013-3007-y


  6 / 150 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:23479940
[Au] Autor:Adamowski T; Kiejna A
[Ad] Endereço:Katedra Psychiatrii UM we Wroclawiu.
[Ti] Título:[Physicians' opinion on the use of perazine in the treatment of mental disorders--results of the Delphi consensus study].
[Ti] Título:Opinie lekarzy dotyczace perazyny w leczeniu zaburzen psychicznych--wyniki badania metoda delficka..
[So] Source:Psychiatr Pol;46(6):985-93, 2012 Nov-Dec.
[Is] ISSN:0033-2674
[Cp] País de publicação:Poland
[La] Idioma:pol
[Ab] Resumo:AIM: Currently, the use of first generation antipsychotics (FGA) is strongly limited. On the other hand, treatment with second generation antipsychotics (SGA) can not be applied in every patient. Therefore, there is an urgent necessity to obtain information about the knowledge and experience of clinicians with regard to safety and efficacy of pernazine, which represents the most widely used FGA in Poland. Due to a striking scarcity of studies on pernazine, authors designed and performed the study, which should provide physicians knowledge arising from daily practice of clinicians included in this study. METHODS: Analysis was performed basing on 142 opinions of 26 physicians who were experienced in the treatment with pernazine. The Delphi method, which relies on concluding from expert opinions was adopted in this study. A three-round Delphi was used in order to yield final conclusions. RESULTS: According to clinicians, pernazine is one of the most cost-effective and well-tolerated FGA. Furthermore, its different profiles of action (anxiolytic and sedative) enable to use pernazine in various indications, as well as in polypharmacotherapy. Referring to a long-term experience, clinicians emphasised the efficacy of pernazine and a high compliance with medication. CONCLUSIONS: Psychiatric treatment should be individualised taking into account not only clinical indices but also patient's preferences and expectations. According to clinicians pernazine is a safe and versatile medication for schizophrenia or other mental disorders and serves as the alternative for SGA.
[Mh] Termos MeSH primário: Antipsicóticos/uso terapêutico
Atitude do Pessoal de Saúde
Transtornos Mentais/tratamento farmacológico
Perazina/uso terapêutico
Padrões de Prática Médica/estatística & dados numéricos
Esquizofrenia/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Consenso
Técnica Delfos
Esquema de Medicação
Feminino
Pesquisas sobre Serviços de Saúde
Seres Humanos
Masculino
Meia-Idade
Polônia
Psiquiatria
Transtornos Psicóticos/tratamento farmacológico
[Pt] Tipo de publicação:CONSENSUS DEVELOPMENT CONFERENCE; ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antipsychotic Agents); 8915147A2B (Perazine)
[Em] Mês de entrada:1304
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130314
[St] Status:MEDLINE


  7 / 150 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:23406770
[Au] Autor:Wójcikowski J; Maurel P; Daniel WA
[Ad] Endereço:Department of Pharmacokinetics and Drug Metabolism, Institute of Pharmacology, Polish Academy of Science, Smetna 12, PL 31-343 Kraków, Poland. wojcikow@if-pan.krakow.pl
[Ti] Título:Autoinduction of the metabolism of phenothiazine neuroleptics in a primary culture of human hepatocytes.
[So] Source:Pharmacol Rep;64(6):1578-83, 2012.
[Is] ISSN:1734-1140
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The metabolism of phenothiazine neuroleptics (promazine, perazine) in a primary culture of human hepatocytes after pretreatment of cells with those neuroleptics was studied. METHODS: The hepatocytes were pretreated with 25 µM promazine or perazine for 96 h. Then, the cells were incubated for 2, 4, 6, 8 and 24 h in the presence of neuroleptics. At the indicated time points, concentrations of phenothiazines and their metabolites (5-sulfoxides and N-desmethyl derivatives) were measured in the culture medium using HPLC with UV detection. RESULTS: Pretreatment of the primary culture of human hepatocytes with promazine or perazine resulted in accumulation of their metabolites in the culture medium. Such an effect was not observed in the case of control cultures (not pretreated with neuroleptics). CONCLUSION: The obtained results suggest that the tested phenothiazines may stimulate their own metabolism by inducing CYP1A2, CYP3A4 and CYP2C19 isoforms.
[Mh] Termos MeSH primário: Antipsicóticos/metabolismo
Sistema Enzimático do Citocromo P-450/biossíntese
Hepatócitos/enzimologia
Perazina/metabolismo
Promazina/metabolismo
[Mh] Termos MeSH secundário: Idoso
Antipsicóticos/farmacologia
Biotransformação
Células Cultivadas
Cromatografia Líquida de Alta Pressão
Remoção de Radical Alquila
Indução Enzimática
Feminino
Hepatócitos/efeitos dos fármacos
Seres Humanos
Isoenzimas
Perazina/farmacologia
Cultura Primária de Células
Promazina/farmacologia
Espectrofotometria Ultravioleta
Sulfóxidos/metabolismo
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Isoenzymes); 0 (Sulfoxides); 8915147A2B (Perazine); 9035-51-2 (Cytochrome P-450 Enzyme System); O9M39HTM5W (Promazine)
[Em] Mês de entrada:1307
[Cu] Atualização por classe:140731
[Lr] Data última revisão:
140731
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130215
[St] Status:MEDLINE


  8 / 150 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23188641
[Au] Autor:Halboos A; Jockenhövel F
[Ad] Endereço:Evangelisches Krankenhaus Herne, Akademisches Lehrkrankenhaus der Universität Duisburg-Essen. a.halboos@evk-herne.de
[Ti] Título:[Complete atrioventricular block during lithium therapy within therapeutic range].
[Ti] Título:Kompletter AV-Block unter Lithiumtherapie im therapeutischen Bereich..
[So] Source:Dtsch Med Wochenschr;137(49):2583-5, 2012 Dec.
[Is] ISSN:1439-4413
[Cp] País de publicação:Germany
[La] Idioma:ger
[Ab] Resumo:HISTORY AND CLINICAL FINDINGS: A 69-year-old man came to the emergency unit because of vertigo and presyncope. A bipolar disorder - known since an age of 15 years - has been treated with 2 × 450 mg lithium and 100 mg perazine per day for several years (no other medications). With the exception of a low heart rate (36/min) clinical examination findings were unremarkable. INVESTIGATIONS: Electrocardiography revealed a permanent complete atrioventricular block with a heart rate of 36/min. Echocardiography showed a normal left ejection fraction (EF 65 %). Laboratory tests were mainly unremarkable, particularly the lithium levels (0,7 mmol/l) were within the therapeutic range. TREATMENT AND COURSE: Continuous treatment with orciprenaline stabilized the heart rate at an average of 52/min. After pacing with a provisional pacemaker a permanent pacemaker was implanted without complications, and the symptoms of vertigo and dizziness disappeared. Pacemaker checkup on the following day still showed a complete atrioventricular block with a heart rate of 28/min. CONCLUSION: Complete atrioventricular block secondary to chronic lithium therapy even in therapeutic levels is a rare complication with poor prognosis. Therefore it should be treated consequently.
[Mh] Termos MeSH primário: Antimaníacos/efeitos adversos
Bloqueio Atrioventricular/induzido quimicamente
Transtorno Bipolar/tratamento farmacológico
Carbonato de Lítio/efeitos adversos
[Mh] Termos MeSH secundário: Idoso
Antimaníacos/farmacocinética
Antimaníacos/uso terapêutico
Bloqueio Atrioventricular/sangue
Bloqueio Atrioventricular/diagnóstico
Bloqueio Atrioventricular/terapia
Transtorno Bipolar/sangue
Relação Dose-Resposta a Droga
Quimioterapia Combinada
Ecocardiografia
Eletrocardiografia/efeitos dos fármacos
Frequência Cardíaca/efeitos dos fármacos
Seres Humanos
Carbonato de Lítio/farmacocinética
Carbonato de Lítio/uso terapêutico
Assistência de Longa Duração
Masculino
Marca-Passo Artificial
Perazina/efeitos adversos
Perazina/uso terapêutico
Prognóstico
Processamento de Sinais Assistido por Computador
[Pt] Tipo de publicação:CASE REPORTS; ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antimanic Agents); 2BMD2GNA4V (Lithium Carbonate); 8915147A2B (Perazine)
[Em] Mês de entrada:1301
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:121129
[St] Status:MEDLINE
[do] DOI:10.1055/s-0032-1327296


  9 / 150 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:22814006
[Au] Autor:Tybura P; Samochowiec A; Beszlej A; Grzywacz A; Mak M; Frydecka D; Bienkowski P; Mierzejewski P; Potemkowski A; Samochowiec J
[Ad] Endereço:Department of Psychiatry, Pomeranian Medical University, Broniewskiego 26, PL 71-460 Szczecin, Poland.
[Ti] Título:Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients.
[So] Source:Pharmacol Rep;64(3):528-35, 2012.
[Is] ISSN:1734-1140
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Therapeutic effects of all clinically used antipsychotics are related to the reduction of dopaminergic transmission in the limbic system. The aim of present study was two-fold. First, efficacy of atypical drugs (ziprasidone and olanzapine) against schizophrenia symptoms was compared to that offered by a typical antipsychotic medication, perazine. Second, associations between some dopaminergic genes polymorphisms and therapeutic response to antipsychotics were assessed in the same group of schizophrenia patients. METHODS: One hundred ninety one Caucasian patients admitted with exacerbation of paranoid schizophrenia were genotyped for polymorphisms of the DRD2 [the ins/del -141C (rs1799732) and exon 8 (rs 71653615)], DRD2/ANKK1 Taq IA(rs 1800497), DAT1 (the 40 bp VNTR), COMT (rs 4680), and MAOA gene (the 30 bp VNTR in promoter). The patients were randomly assigned to the treatment with perazine, olanzapine or ziprasidone given as monotherapy for 3 months. Treatment efficacy was measured from baseline (T0) to T1 (14 days) and T2 (3 months). A retention rate was also assessed at T1 and T2. RESULTS: The three antipsychotics did not differ in terms of reduction of the PANSS score or retention rate at the follow-up. There was no interaction between the investigated polymorphisms and response to the antipsychotic treatment. CONCLUSIONS: The present results suggest that: i) there are no major differences in short-term efficacy or effectiveness of atypical (olanzapine, ziprasidone) and typical (perazine) antipsychotic drugs; ii) the studied polymorphisms are not primarily involved in treatment response to antipsychotics in schizophrenia patients.
[Mh] Termos MeSH primário: Antipsicóticos/uso terapêutico
Dopamina/metabolismo
Esquizofrenia Paranoide/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Benzodiazepinas/uso terapêutico
Antagonistas de Dopamina/uso terapêutico
Feminino
Seguimentos
Genótipo
Seres Humanos
Masculino
Meia-Idade
Perazina/uso terapêutico
Piperazinas/uso terapêutico
Polimorfismo Genético
Esquizofrenia Paranoide/genética
Tiazóis/uso terapêutico
Fatores de Tempo
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Dopamine Antagonists); 0 (Piperazines); 0 (Thiazoles); 12794-10-4 (Benzodiazepines); 6UKA5VEJ6X (ziprasidone); 8915147A2B (Perazine); N7U69T4SZR (olanzapine); VTD58H1Z2X (Dopamine)
[Em] Mês de entrada:1301
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120721
[St] Status:MEDLINE


  10 / 150 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
[PMID]:22207119
[Au] Autor:Kucharska-Pietura K; Tylec A; Czernikiewicz A; Mortimer A
[Ad] Endereço:Department of Mental Health, Hull York Medical School, Grimsby, UK.
[Ti] Título:Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs.
[So] Source:Med Sci Monit;18(1):CR44-49, 2012 Jan.
[Is] ISSN:1643-3750
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Effectiveness of antipsychotics in treating emotional and cognitive deficits in schizophrenia still remains controversial. The aim of our study was to assess emotional and cognitive functioning in schizophrenic inpatients currently treated with typical antipsychotics (perphenazine, perazine, fluphenazine, and haloperidol) and in another group of schizophrenic inpatients currently on atypical antipsychotics (olanzapine, risperidone, amisulpride, and quetiapine). MATERIAL/METHODS: One hundred patients with DSM-IV schizophrenia or schizoaffective disorders (39 treated using typical antipsychotics and 61 treated with atypical antipsychotics) under naturalistic treatment conditions, and 50 healthy controls were given the following: Test of Everyday Attention, Facial Emotion Recognition Test, Facial Memory Recognition Test, and "Reading the mind in the eyes" Test. RESULTS: Patients with a diagnosis of schizophrenia revealed the following deficits: facial emotion perception, empathy /theory of mind, visual selective attention/speed, attentional switching, and auditory-verbal working memory. Our results show a significant difference between schizophrenic and healthy controls in all tasks, with schizophrenic patients performing worse than controls. Interestingly, our patients on atypical neuroleptics performed similarly compared to schizophrenic patients treated with conventional neuroleptics on all tasks provided. There were some significant relationships between emotional and cognitive deficits and clinical variables. CONCLUSIONS: Our findings remain consistent with other recent studies in which atypical antipsychotics did not show a clear advantage over typical antipsychotics on both emotional and cognitive functioning.
[Mh] Termos MeSH primário: Antipsicóticos/farmacologia
Atenção/fisiologia
Emoções/fisiologia
Esquizofrenia/tratamento farmacológico
Esquizofrenia/fisiopatologia
[Mh] Termos MeSH secundário: Adulto
Análise de Variância
Antipsicóticos/uso terapêutico
Atenção/efeitos dos fármacos
Benzodiazepinas
Dibenzotiazepinas
Emoções/efeitos dos fármacos
Flufenazina
Haloperidol
Seres Humanos
Memória/fisiologia
Meia-Idade
Perazina
Perfenazina
Fumarato de Quetiapina
Recognição (Psicologia)/fisiologia
Risperidona
Sulpirida/análogos & derivados
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Dibenzothiazepines); 12794-10-4 (Benzodiazepines); 2S3PL1B6UJ (Quetiapine Fumarate); 7MNE9M8287 (Sulpiride); 8915147A2B (Perazine); AA0G3TW31W (sultopride); FTA7XXY4EZ (Perphenazine); J6292F8L3D (Haloperidol); L6UH7ZF8HC (Risperidone); N7U69T4SZR (olanzapine); S79426A41Z (Fluphenazine)
[Em] Mês de entrada:1204
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:111231
[St] Status:MEDLINE



página 1 de 15 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde